Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer

A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.

The J&J combination contains Rybrevant and a new drug called Lazcluze, or lazertinib. Tuesday, J&J said the FDA has approved the regimen for newly diagnosed non-small cell lung cancer patients with one of the two common EGFR mutations at exon 19 or exon 21.